A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS).
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Vatalanib (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 21 Jun 2011 Planned end date changed from 1 Jun 2005 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.